Olema Pharmaceuticals (OLMA) is a pre-revenue oncology biotech with one pivotal asset — palazestrant, the first true oral CERAN (Complete ER Antagonist) in Phase 3 for ER+/HER2- metastatic breast cancer. The stock dropped 35% from January highs ($22.65) to $13 in March on no fundamental news. The Q1 2026 10-Q (filed May 12) maintained the path to a fall 2026 OPERA-01 readout. Two adjacent catalysts hit in 18 days.

What the filing says

Cash $505.3M at March 31. Management explicit: "will enable us to fund our current operating plan through mid-2028." Q1 burn $46M operating, $49.2M R&D (+61% YoY). The mid-2028 horizon extends past OPERA-01 readout, NDA filing (2027), and the late-2027 launch target.

OPERA-01 timeline narrowed from "second half of 2026" to "fall of 2026." Comparator confirmed: classic endocrine therapy only — fulvestrant, anastrozole, letrozole, exemestane. Imlunestrant not allowed in the SoC arm.

OPERA-02 confirmed as a pivotal Phase 3 — palazestrant + ribociclib in 1L ER+/HER2- MBC, top-line guided 2028. Previously ambiguous; now an explicit second pivotal on the same molecule.

ATM raised $41.9M at $24.92/share average in Q1 — equity sold to the market at nearly 2x current price. OP-3136 (KAT6A/B inhibitor) Phase 1 data at ASCO 2026, May 30 poster.

What the market thinks

Stock ≈$13. Solving with midpoint hit/miss targets ($35 / $7): market-implied P(OPERA-01 hits) ≈ 21%.

Bottoms-up probability-weighted fair value (across all-comer hit / ESR1m-only / miss states, plus M&A multiplier and pipeline NPV): ≈$19. The worldview scenario sits at $26. Anchor range $19-26, midpoint ≈$22. Upside to midpoint: ≈70%.

Thesis P(OPERA-01 hits at least one population) is roughly 40-50% — CERAN-adjusted with dual-endpoint structure. Gap: 20-30 percentage points on a binary.

Why the gap may exist

Class base rate skepticism. 0/5 all-comer oral SERDs have succeeded in Phase 3 (elacestrant, giredestrant, imlunestrant, amcenestrant, rintodestrant). The market correctly weights this.

Mechanism differentiation underweighted. Palazestrant is the first true CERAN in Phase 3 — full AF1+AF2 blockade via N-CoR/SMRT corepressor recruitment, zero partial agonist activity, DC50 < 1 nmol/L. The class failures are SERM/SERDs with residual agonist activity. CERAN is designed for that specific failure mode.

Competitive slot misread. VEPPANU (vepdegestrant) approved Q2 2026 with ESR1m-only label; Pfizer/Arvinas cancelled the atirmociclib and CDK4/6i combo Phase 3 trials in Q1 2025 and jointly out-licensed. LLY imlunestrant Q1 launch was tepid — buried in a 7-product list, no standalone revenue, sole metric was "35% share of oral 3L new patient starts" in ESR1m. The all-comer 2L/3L slot is contested by exactly one other Phase 3: AZN SERENA-4 (1L, H2 2026).

PERSEVERA read-through. AZN's Susan Galbraith on the Q1 2026 call explicitly flagged PERSEVERA at ASCO 2026 as the closest oral SERD Phase 3 design analog. The trial reads in 18 days.

Forced-seller residual (hypothesis). March -35% selloff came without news. ATM at $24.92 captures part of the dislocation. 13F deadline May 15-16 may identify the seller — unverified until then.

Risks (ranked by impact)

1. OPERA-01 misses primary endpoint. Class base rate is data; mechanism is theory. Bear case = $5-7.
2. No insider buying at $13. Form 4 sales were 10b5-1 conversions at $23-29; zero P-code purchases at trough. Either insiders see $13 as fair, or pre-ASCO blackout.
3. Single-asset concentration. Palazestrant fails → -65% to -70%. OP-3136 is pipeline garnish; OPERA-02 is the same molecule.
4. PERSEVERA misses ITT cleanly. Drags OLMA 10-15% lower in days. P(clean ITT hit, HR <0.70) ≈ 25%.
5. R&D burn +61% YoY. Mid-2028 guidance assumes this rate, not acceleration.

Catalysts

• May 15-16, 2026 — Q1 13F deadline. Informational.
• May 29 – Jun 2, 2026 — ASCO 2026:
  • May 30: OP-3136 Phase 1 poster (Abstract 3088)
  • May 29 – Jun 2: PERSEVERA Phase 3 ITT readout
  • Jun 1: OPERA-02 trial-in-progress poster
• Aug 31, 2026 — Target for OPERA-01 enrollment-complete 8-K.
• Fall 2026 — OPERA-01 top-line PFS readout. Terminal binary.
• 2027 — NDA. Late 2027 — US approval target.
• 2028 — OPERA-02 readout.

What would change our mind

• Form 4 P-code insider purchase at $13. Currently absent.
• PERSEVERA ITT HR <0.70 at ASCO: strong de-risk for OPERA-01 analog.
• PERSEVERA misses both populations cleanly: CERAN class probability repriced down.
• Cash guidance contraction to <12mo: capital-floor thesis reverses.
• New Form 4 cluster sells, not 10b5-1: bearish information signal.

Evidence

LR signal: 1.3 — mildly bullish. The class base rate is the real bear; CERAN differentiation is unverified pre-data. Capital should overweight vs the ≈21% market-implied probability, but conviction is bounded by clinical uncertainty.